참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Levonorgestrel | HCID 13109 | — |
| 반응물 | Hydroxylamine HCl | HCID 21645 | — |
| 반응물 | (17Beta)-13-Ethyl-3-methoxygona-2,5(10)-dien-17-ol | HCID 101950 | — |
| 반응물 | 13-Ethyl-3-(hydroxyimino)-gon-4-ene-17beta-ol | HCID 86596451 | — |
| 용매 | Pyridine | HCID 1049 | — |
| 생성물 | Norelgestromin (USAN:INN:BAN) | HCID 9568628 | — |
반응 단계
Hungarian Patent No. 165356 describes the synthesis of dl- as well as d-norgestrel. The starting material of the synthesis is the racemic or the optically active 13-ethyl-3-methoxygona-2,5(10)-diene-17β-ol, which is reacted with hydroxylammonium chloride in pyridine at 100° C. Then the obtained 13-ethyl-3-(hydroxyimino)-gon-4-ene-17β-ol is oxidized at position 17, followed by ethinylation of the oxo group at position 17, to give the dl-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-oxime, or norelgestromin. Although the synthesis of the intermediates, the dl-(17α)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yn-3-one-oxime and norelgestromin, are described, the identification and the purity (the quality requirements) as well as the pharmacological activity of these compounds are not provided.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US07816546B2 |
|---|
| 출처 데이터셋 | uspto-grants-2010_10 |
|---|
| ORD ID | ord-6fc91d3964df413fb7a6b740b57eb5b2 |
|---|
| 출처 메모 | uspto-grants-2010_10 |
|---|